Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Apalutamide/ADT prolongs PSA PFS in biochemically relapsed prostate cancer
May 2nd 2023Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.
Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBC
December 2nd 2022Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.
Selectivity of patients, dosing play a role in the future evaluation of PSMA combinations in mCRPC
December 1st 2022The combination use of PSMA-targeted radionuclide therapy tailored by the individual patient and dose may show promise in the future treatment of men with metastatic castration-resistant prostate cancer.
HoLEP improves outcomes in patients with LUTS related to benign prostatic enlargement
May 15th 2022“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”
Novel oncolytic immunotherapy plus pembrolizumab active in BCG-unresponsive NMIBC
April 13th 2022Early findings from the phase 2 CORE1 trial showed that the combination of the novel oncolytic immunotherapy CG0070 and the immune checkpoint inhibitor pembrolizumab was safe and active in patients with BGG-unresponsive NMIBC.
Genetically-adjusted PSA may address overdiagnosis/overtreatment issues of prostate cancer screening
April 11th 2022Results shared during the 2022 AACR Annual Meeting suggested that genetic adjustment of prostate-specific antigen may reduce overdiagnosis of prostate cancer, de-escalate invasive testing, and improve the detection of aggressive disease.
Longer follow-up shows improved DFS with nivolumab in high-risk muscle-invasive urothelial carcinoma
December 1st 2021According to extended follow-up from the phase 3 Checkmate 274 trial, nivolumab continued to demonstrate improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.
Around the Practice: Expert Offers Update in Genitourinary Cancer Cases
May 18th 2021Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.